TY - JOUR T1 - Expression of Nogo Isoforms and Nogo-B Receptor (NgBR) in Non-small Cell Lung Carcinomas JF - Anticancer Research JO - Anticancer Res SP - 4059 LP - 4068 VL - 34 IS - 8 AU - BARTOSZ PULA AU - BOZENA WERYNSKA AU - MATEUSZ OLBROMSKI AU - BEATA MUSZCZYNSKA-BERNHARD AU - MARIUSZ CHABOWSKI AU - DARIUSZ JANCZAK AU - MACIEJ ZABEL AU - MARZENA PODHORSKA-OKOLOW AU - PIOTR DZIEGIEL Y1 - 2014/08/01 UR - http://ar.iiarjournals.org/content/34/8/4059.abstract N2 - Background: Nogo-B was recently shown to be involved in proliferation, apoptosis and invasiveness of cancer cells, whereas its specific receptor (NgBR) was found to be up-regulated in estrogen receptor-α positive breast cancer. No data are currently available concerning their expression in non-small cell lung carcinomas (NSCLC). Materials and Methods: Expression of Nogo isoforms and NgBR was studied in 191 NSCLC. Results: Higher Nogo-A/B immunoreactivity was noted in cancer cells of squamous cell carcinomas (SQC) compared to adenocarcinomas (p<0.001). Stage II-IV tumors had the lowest Nogo-A/B expression (p<0.0001) compared to stage I cases. Nogo-A/B expression decreased with increasing SQC malignancy grade (p=0.026). Significant NgBR mRNA down-regulation was associated with larger primary tumor size (p=0.039), lymph node involvement (p=0.039) and advancement stage (p=0.0054). Low NgBR mRNA expression predicted poor patients outcome (p=0.029). Conclusion: The current data may point to the involvement of Nogo isoforms and NgBR in the pathogenesis of NSCLC. ER -